Highlights Aug 17 - Aug 23, 2026
new every Sunday
This week brought early clinical evidence in anorexia, major pharma backing for non-hallucinogenic neuroplastogens, and research challenging familiar assumptions about psychedelic history and ritual. New theoretical work also examined how psilocybin may alter the sense of self.
-
01
Psilocybin treatment in people with anorexia nervosa showed feasibility, acceptable safety, and possible symptom relief in an early clinical study
An early study found psilocybin feasible and acceptably safe in anorexia, with possible symptom relief but no proof of efficacy.
-
02
Johnson & Johnson is set to lead Delix Therapeutics' $85 million Series C, signaling major pharma backing for non-hallucinogenic neuroplastogens
Johnson & Johnson's reported $85 million investment signals major pharma interest in neuroplastogens without hallucinogenic effects.
-
03
Studie findet keine historischen Belege fuer eine angeblich uralte Nutzung von Kroetenmedizin und ordnet die Erzaehlung um 5-MeO-DMT kulturgeschichtlich neu ein
Historical research finds no solid evidence for an ancient, continuous toad-medicine tradition, reframing claims around 5-MeO-DMT.
-
04
Ceremony length tracks drug duration across 11 traditions, linking psychedelic pharmacology with ritual structure and community response
Across 11 traditions, ceremony length tracked drug duration, linking pharmacology to ritual structure and collective response.
-
05
Psilocybin alters consciousness by loosening the brain's ordinary predictive control, increasing uncertainty and promoting a felt sense of oneness
A predictive-processing account links psilocybin's disruption of self-models to uncertainty, ego dissolution, and connectedness.